ALKS Alkermes plc
Stock · NasdaqGS · Ireland · Healthcare · IE00B56GVS15
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Alkermes plc, and has no access to any account you may have with it. The name and the logo belong to their owners.
Price
45.90 USD
+3.05%
52-week range
27.00 – 55.67
Dividend yield—
Market cap7.7B
NowoTrade score
45 Grade A
Price history
Daily prices in USD.
Updated 08 Nov 2026 14:27. Information, not advice.
Results
Next results
24 Feb 2027
in 108 days · 08:00 · estimate 0.16
Last results
0.57 vs 0.25 estimated
03 Nov 2026 · Beat +130.9%
Beat the estimate
9 of 12
2 missed · 1 in line · 9 beats in a row
Average surprise
+121.0%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 24 Feb 2027 08:00 | 0.16 | — | — | Upcoming |
| 03 Nov 2026 08:00 | 0.25 | 0.57 | +130.9% | Beat |
| 28 Jul 2026 07:00 | 0.29 | 0.70 | +141.3% | Beat |
| 05 May 2026 07:00 | -0.04 | 0.38 | +1,053.0% | Beat |
| 25 Feb 2026 07:00 | 0.45 | 0.48 | +7.7% | Beat |
| 28 Oct 2025 07:00 | 0.39 | 0.65 | +68.5% | Beat |
| 29 Jul 2025 07:00 | 0.40 | 0.68 | +71.1% | Beat |
| 01 May 2025 07:00 | 0.24 | 0.29 | +18.9% | Beat |
| 12 Feb 2025 07:00 | 0.76 | 1.05 | +37.6% | Beat |
| 24 Oct 2024 07:00 | 0.71 | 0.73 | +2.4% | Beat |
| 24 Jul 2024 07:00 | 0.71 | 0.70 | -0.8% | In line |
| 01 May 2024 07:00 | 0.58 | 0.43 | -26.2% | Miss |
| 15 Feb 2024 07:00 | 0.46 | 0.22 | -52.0% | Miss |
| 25 Oct 2023 07:00 | 0.43 | 0.64 | +50.2% | Beat |
| 26 Jul 2023 07:00 | 0.64 | 0.55 | -13.8% | Miss |
| 26 Apr 2023 07:00 | -0.01 | 0.01 | +180.0% | Beat |
| 16 Feb 2023 07:00 | 0.05 | 0.14 | +210.8% | Beat |
| 02 Nov 2022 07:00 | 0.03 | 0.02 | -32.8% | Miss |
| 27 Jul 2022 07:00 | 0.05 | 0.06 | +26.7% | Beat |
| 27 Apr 2022 07:00 | 0.03 | 0.12 | +380.0% | Beat |
| 16 Feb 2022 07:00 | 0.13 | 0.23 | +72.5% | Beat |
| 27 Oct 2021 07:00 | 0.10 | 0.14 | +46.3% | Beat |
| 28 Jul 2021 07:00 | 0.12 | 0.30 | +142.4% | Beat |
| 28 Apr 2021 07:00 | -0.02 | 0.11 | +718.7% | Beat |
| 11 Feb 2021 07:00 | 0.07 | 0.10 | +43.8% | Beat |
| 29 Oct 2020 07:00 | — | 0.26 | +12,900.0% | Beat |
| 29 Jul 2020 07:00 | — | 0.06 | +4,411.3% | Beat |
| 29 Apr 2020 08:00 | -0.05 | 0.01 | +122.0% | Beat |
| 13 Feb 2020 07:00 | 0.66 | 0.83 | +26.4% | Beat |
| 23 Oct 2019 07:00 | -0.21 | -0.04 | +80.6% | Beat |
| 25 Jul 2019 07:00 | -0.12 | 0.09 | +176.9% | Beat |
| 25 Apr 2019 07:00 | -0.17 | -0.17 | -0.6% | In line |
| 14 Feb 2019 07:00 | -0.05 | 0.34 | +724.1% | Beat |
| 23 Oct 2018 07:00 | -0.08 | 0.07 | +192.9% | Beat |
| 26 Jul 2018 07:00 | 0.13 | 0.29 | +116.0% | Beat |
| 26 Apr 2018 07:00 | -0.09 | -0.09 | +4.8% | Beat |
| 14 Feb 2018 07:00 | 0.27 | 0.31 | +16.6% | Beat |
| 26 Oct 2017 07:00 | -0.01 | 0.03 | +494.7% | Beat |
| 27 Jul 2017 07:00 | -0.01 | 0.01 | +167.8% | Beat |
| 27 Apr 2017 07:00 | -0.09 | -0.18 | -99.3% | Miss |
| 15 Feb 2017 07:00 | 0.05 | 0.15 | +174.8% | Beat |
| 02 Nov 2016 07:00 | -0.04 | -0.09 | -154.7% | Miss |
| 28 Jul 2016 07:00 | -0.10 | -0.01 | +90.0% | Beat |
| 28 Apr 2016 07:00 | -0.20 | -0.16 | +21.5% | Beat |
| 25 Feb 2016 07:00 | -0.24 | -0.15 | +38.0% | Beat |
| 29 Oct 2015 07:00 | -0.21 | -0.18 | +14.4% | Beat |
| 30 Jul 2015 07:00 | -0.10 | -0.09 | +5.8% | Beat |
| 30 Apr 2015 07:00 | -0.05 | 0.06 | +230.9% | Beat |
| 24 Feb 2015 07:00 | 0.04 | 0.11 | +160.9% | Beat |
| 29 Oct 2014 07:00 | 0.02 | 0.03 | +44.7% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 1.5B | -5.2% | 241.7M | 16.4% | 1.43 | -34.1% | 480.3M |
| 2024 | 1.6B | -6.4% | 367.1M | 23.6% | 2.17 | +3.3% | 405.6M |
| 2023 | 1.7B | +49.6% | 355.8M | 21.4% | 2.10 | +316.5% | 353.3M |
| 2022 | 1.1B | — | -158.3M | -14.2% | -0.97 | — | -17.2M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 26 Jun 2023 – 30 Jun 2023 | 33.71 | 33.71 | 30.98 | 31.30 | -6.12% | 8,620,300 | |
| 20 Jun 2023 – 23 Jun 2023 | 32.34 | 33.67 | 31.85 | 33.34 | +3.57% | 7,179,600 | |
| 12 Jun 2023 – 16 Jun 2023 | 31.28 | 32.41 | 30.97 | 32.19 | +3.41% | 6,275,400 | |
| 05 Jun 2023 – 09 Jun 2023 | 29.29 | 32.28 | 29.21 | 31.13 | +5.49% | 7,586,500 | |
| 30 May 2023 – 02 Jun 2023 | 29.11 | 29.64 | 28.56 | 29.51 | +0.65% | 4,128,300 | |
| 22 May 2023 – 26 May 2023 | 30.48 | 30.65 | 29.05 | 29.32 | -3.81% | 4,052,900 | |
| 15 May 2023 – 19 May 2023 | 31.23 | 31.34 | 29.98 | 30.48 | -2.18% | 5,263,100 | |
| 08 May 2023 – 12 May 2023 | 29.46 | 31.47 | 29.38 | 31.16 | +5.81% | 7,004,100 | |
| 01 May 2023 – 05 May 2023 | 28.61 | 29.49 | 28.01 | 29.45 | +3.15% | 5,683,900 | |
| 24 Apr 2023 – 28 Apr 2023 | 29.30 | 30.75 | 27.68 | 28.55 | -2.83% | 9,556,800 | |
| 17 Apr 2023 – 21 Apr 2023 | 29.57 | 29.86 | 28.82 | 29.38 | +0.10% | 5,730,800 | |
| 10 Apr 2023 – 14 Apr 2023 | 29.05 | 29.99 | 28.75 | 29.35 | +0.44% | 10,447,700 | |
| 03 Apr 2023 – 06 Apr 2023 | 28.06 | 29.68 | 27.81 | 29.22 | +3.65% | 4,554,900 | |
| 27 Mar 2023 – 31 Mar 2023 | 26.59 | 28.27 | 26.45 | 28.19 | +6.42% | 6,100,900 | |
| 20 Mar 2023 – 24 Mar 2023 | 26.18 | 26.87 | 25.43 | 26.49 | +1.77% | 4,128,000 | |
| 13 Mar 2023 – 17 Mar 2023 | 26.44 | 27.25 | 25.98 | 26.03 | -2.18% | 6,147,400 | |
| 06 Mar 2023 – 10 Mar 2023 | 27.07 | 27.38 | 26.01 | 26.61 | -2.35% | 4,876,800 | |
| 27 Feb 2023 – 03 Mar 2023 | 27.26 | 27.56 | 26.72 | 27.25 | +0.26% | 5,766,200 | |
| 21 Feb 2023 – 24 Feb 2023 | 27.89 | 28.17 | 27.00 | 27.18 | -3.17% | 5,356,800 | |
| 13 Feb 2023 – 17 Feb 2023 | 27.14 | 29.49 | 26.53 | 28.07 | +3.62% | 8,598,300 | |
| 06 Feb 2023 – 10 Feb 2023 | 27.33 | 28.30 | 26.59 | 27.09 | -0.95% | 5,021,300 | |
| 30 Jan 2023 – 03 Feb 2023 | 29.04 | 29.28 | 27.27 | 27.35 | -5.75% | 5,272,900 | |
| 23 Jan 2023 – 27 Jan 2023 | 27.60 | 29.05 | 27.05 | 29.02 | +4.69% | 6,344,400 | |
| 17 Jan 2023 – 20 Jan 2023 | 27.94 | 28.82 | 27.26 | 27.72 | +1.50% | 7,729,100 | |
| 09 Jan 2023 – 13 Jan 2023 | 27.01 | 27.61 | 25.87 | 27.31 | +0.74% | 7,960,100 |
Page 8 of 11
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Alkermes Showcases Research From Psychiatry and Sleep Portfolios at the Neuroscience Education Institute Fall Congress (opens in a new tab) 05 Nov 2026 12:00
- Alkermes plc 2026 Q3 - Results - Earnings Call Presentation (opens in a new tab) SeekingAlpha · 05 Nov 2026 02:04
- Alkermes (ALKS) Stock Could Be Overvalued Following ALKS 7290 Trial Launch (opens in a new tab) Simply Wall St. · 04 Nov 2026 12:15
- RBC Capital Maintains Outperform on Alkermes, Raises Price Target to $57 (opens in a new tab) Benzinga · 04 Nov 2026 12:11
- Wells Fargo Maintains Overweight on Alkermes, Raises Price Target to $68 (opens in a new tab) Benzinga · 04 Nov 2026 11:41
- HC Wainwright & Co. Maintains Neutral on Alkermes, Raises Price Target to $50 (opens in a new tab) Benzinga · 04 Nov 2026 08:37
- Alkermes PLC (ALKS) Q3 2026 Earnings Call Highlights: Proprietary Sales Surge 31% as Orexin ... (opens in a new tab) GuruFocus.com · 04 Nov 2026 03:04
- Alkermes (ALKS) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 03 Nov 2026 21:28
- Alkermes to Present at Upcoming Investor Conferences (opens in a new tab) 03 Nov 2026 21:00
- Alkermes plc (ALKS) Q3 2026 Earnings Call Transcript (opens in a new tab) SeekingAlpha · 03 Nov 2026 19:15
- What Alkermes (ALKS) Said on Its Q3 Earnings Call (opens in a new tab) MarketBeat · 03 Nov 2026 18:14
- Alkermes plc Q3 2026 Earnings Call Summary (opens in a new tab) Moby · 03 Nov 2026 17:49
- Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say (opens in a new tab) Zacks · 03 Nov 2026 13:30
- Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates (opens in a new tab) Zacks · 03 Nov 2026 12:15
- Alkermes: Q3 Earnings Snapshot (opens in a new tab) Associated Press · 03 Nov 2026 12:12
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 44.54 USD
- Market cap
- 7.7B
- Exchange
- NasdaqGS
- Country
- Ireland
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 16.5 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 17.3 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 5.4 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Revenue has fallen two years in a row
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 6 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | 33.92× | Weak | 14.89× |
| Price / book | 4.14× | Weak | 3.8× |
| Price / sales | 4.4× | Fair | 3.19× |
| EV / EBITDA | 30.28× | Weak | 12.61× |
| Free cash flow yield | 3% | Fair | 2.5% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 87% | Good | 58.6% |
| Operating margin | 13.9% | Fair | 7.6% |
| Net margin | 0% | Weak | 2.7% |
| Return on equity | 0% | Weak | 5.7% |
| Return on assets | 3.7% | Fair | 3.5% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 9.9% | Good | 10.8% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.84× | Fair | 0.48× |
| Net debt / EBITDA | 2.9× | Fair | 1.6× |
| Interest cover | 20.69× | Good | 2.65× |
| Current ratio | 2.43× | Good | 2.36× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow ALKS and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.